AHA Scientific Sessions Daily News 2

SEE PAGES 10-11 FOR HIGHLIGHTS OF THE 2018 GUIDELINE ON THE MANAGEMENT OF BLOOD CHOLESTEROL. November 10-12 | Chicago, Illinois #AHA18 scientificsessions.org SUNDAY | NOVEMBER 11, 2018 M arine omega-3 fatty acids may provide a cardioprotective role, while vitamin D3 supplementation appears to benefit cancer mortality, according to principal results from the National Institutes of Health-funded VITamin D and OmegA-3 TriaL Results of the more than five- year large clinical trial were presented Saturday by JoAnn E. Manson, MD, DrPH, in the Late-Breaking Clinical Trial session, “The VITamin D and OmegA-3 TriaL (VITAL): Principal Results for Vitamin D and Omega-3 Fatty Acid Sup- plementation in the Primary Prevention of Cardiovascular Disease and Cancer.” It was funded by the National Heart, Lung, and Blood Institute and the National Cancer Institute. VITAL is one of only two large, randomized clinical trials of vitamin D for the prevention of cancer, heart disease and stroke — and the only such trial in a racially and ethnically diverse study population. Similarly, it’s the only large trial of fish oil supplements in a generally healthy population. Diagnose and treat ‘residual inflammatory risk’ aggressively T hirty years of translational efforts by the vascular biology community provide cardiologists proof-of-principle that anti- inflammatory therapies can significantly lower cardiovascular events, said Distinguished Scientist Lecturer Paul Ridker, MD. “For the past 40 years, we have focused with enormous success on cholesterol reduction and the treatment of ‘residual cholesterol risk,’” said Ridker, the Eugene Braunwald Professor of Medicine at Harvard Medical School in Cambridge, Massachusetts. “Yet today, we know that for every statin-treated patient who still has a high LDL cholesterol, there are at least three others at risk because of a persistent pro- inflammatory response,” he said. “These ‘residual inflammatory risk’ patients are common, have a differ- ent underlying biology and require a different approach to treatment.” Proof-of-principle for the inflammation hypothesis of atherothrombosis comes from the 10,000-patient Canakinumab Paul Dudley White lecturer to reflect on history of heart transplants B efore the first human heart transplant 51 years ago, the procedure was considered a fantasy. Today, it may not even be the primary or best option, according to Sir Magdi Yacoub, OM, FRS. Yacoub will address the issue in today’s Paul Dudley White International Lecture, “Reflec- tions and Aspirations: Lessons From 4,000 Years.” “Being one of the individuals who witnessed and enthusias- tically got involved in the first human heart transplant, it seems appropriate to reflect on this experience and to use it to cau- tiously look into the future,” said JoAnn E. Manson, MD, DrPH Yacoub see VITAL , page 15 TOP PICKS from the Program Chair AND LBCS schedule 2 Ridker Paul Dudley White International Lecture 3:45-5 p.m. Sunday Room N226 UPCOMING SESSION INSIDE see RIDKER , page 5 see LECTURE , page 17 VITAL trial considers omega-3 fatty acids, vitamin D in CV protection and cancer mortality DISTINGUISHED SCIENTIST LECTURE Thanks for your patience! Our apologies for long registration lines at #AHA18 Saturday morning. The Scientific Sessions team encountered an unanticipated surge in walk-up registration while also experiencing a systems failure. Conference organizers temporarily suspended registration and opened the Saturday pro- gramming so that attendees could participate and bypass the long lines. Science & Technology Hall map and exhibitor list 18 Hypertension Guidelines: Does one size fit all? 3